Annual Congress Munich 2006

Saturday, 02.09.2006
Sunday, 03.09.2006
Monday, 04.09.2006
Tuesday, 05.09.2006
Wednesday, 06.09.2006

Citations should be made in the following way: Authors. Title. Eur Respir J 2006; 28: Suppl. 50, abstract number.

Material from 2006:

4395 Abstracts
610 Slide presentations
175 Webcasts
95 Handouts
175 Multimedia files

Material from 2006: Show

Pulmonary arterial hypertension: from bench back to bedside

Poster Discussion
Chairs: M. Humbert (Clamart, France), J. Pepke-Zaba (Cambridge, United Kingdom)

Download all media

Haemodynamic characteristics of patients with sickle cell disease and suspected pulmonary hypertension on the basis of a tricuspid regurgitation jet velocity >2.5 m/s on doppler echocardiography F. Parent, S. Egels, B. Sztrymf, R. Girot, F. Driss, F. Galacteros, G. Simonneau (Clamart, Paris, Le Kremlin Bicêtre, Créteil, France)
Pulmonary hypertension in children with sickle cell disease: how common is it? R. A. Chaudry, T. Karu, C. Hutchinson, S. Ball, G. Sutherland, A. Bush, M. Rosenthal, S. Crowley (London, United Kingdom)
Prevalence of pulmonary arterial hypertension in HIV positive outpatients in the HAART era O. Sitbon, C. Lascoux-Combe, D. Sereni, F. Raffi, P. Yeni, V. Gressin, P. Clerson, J. F. Delfraissy, G. Simonneau (Clamart, Paris, Nantes, Roubaix, Le Kremlin Bicetre, France)
Epidemiology of pulmonary hypertension: new data from the Swiss registry C. Tueller, H. Stricker, P. Soccal, M. Tamm, J. D. Aubert, M. Maggiorini, L. Nicod, the Swiss Society for Pulmonary Hypertension (Bern, Locarno, Geneva, Basel, Lausanne, Zurich, Switzerland)
Response of plasma von Willebrand factor to systemic endothelial injury in pulmonary arterial hypertension D. Montani, R. Souza, M. Wolf, O. Sitbon, G. Simonneau, M. Humbert (Clamart, France)
Low T3-syndrome and respiratory muscle dysfunction in patients with pulmonary arterial hypertension A. A. Filusch, P. P. Schoene, K. K. Kapadocha, W. R. Rita, H. H. A. Katus, J. F. J. Meyer (Heidelberg, Germany)
Influence of hypoxia-induced pulmonary hypertension on the domiciliation of infused mesenchymal stem cells in rats G. Y. Rochefort, P. Vaudin, N. Bonnet, J. C. Pagès, J. Domenech, P. Charbord, V. Eder (Tours, Orléans, France)
Pulmonary arterial hypertension phenotype in VIP knockout mice S. A. Hamidi, A. M. Szema, K. G. Dickman, S. Lyubsky, R. Z. Lin, Y. P. Jiang, S. Kort, S. I. Said (Northport, Stony Brook, United States Of America)
Circulating fibrocytes: a role in pulmonary circulation? V. S. Nikam, K. Ahlbrecht, N. Weissmann, P. Koenig, J. Lohmeyer, W. Seeger, R. Voswinckel (Giessen, Germany)
Characteristics of the hepatopulmonary syndrome in cirrhotic patients, pre and postransplantation E. Márquez, P. Cejudo, R. Tallón, F. Ortega, J. L. López-Campos, I. López, L. Jara, J. M. Pascasio, E. Rodriguez (Seville, Spain)
Role of nitric oxide in hepatopulmonary syndrome H. A. Makhlouf, A. A. R. Mohamed-Hussein, M. E. A. A. Ibrahim, S. M. Wafy, N. T. Elmelegy, M. A. Ashry (Assiut, Egypt)
The pattern of response in acute vasodilator test in portopulmonary hypertension (PoPH) G. L. Ricci, M. T. Melgosa, F. Burgos, J. L. Valera, S. Pizarro, J. Roca, R. Rodriguez-Roisin, J. A. Barbera‘ (Rome, Italy; Barcelona, Spain)
Acute effects of inhaled iloprost in portopulmonary hypertension M. T. Melgosa, J. C. Garcia-Pagan, J. L. Valera, J. Turnes, G. Ricci, J. Roca, R. Rodriguez-Roisin, J. A. Barberà (Barcelona, Spain)
Effect of the Asp²⁹⁸ variant of endothelial nitric oxide synthase on acute pulmonary vasodilator testing response in idiopathic pulmonary arterial hypertension P. Jansa, M. Jachymova, D. Ambroz, A. Linhart, M. Aschermann (Prague, Czech Republic)
Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension S. C. Mathai, T. Housten-Harris, R. E. Girgis, P. M. Hassoun (Baltimore, United States Of America)
*Treatment effects of Rho-kinase (Rock) inhibition vs.* phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension** K. T. B. Mouchaers, I. Schalij, G. P. van Nieuw Amerongen, W. J. van der Laarse, A. Vonk-Noordegraaf (Amsterdam, Netherlands)
Responses to sitaxsentan in patients with functional class II compared to III/IV pulmonary arterial hypertension I. R. Preston, N. S. Hill (Boston, United States Of America)
Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction A. V. Volkov, E. L. Nasonov (Moscow, Russian Federation)
Lung function and pulmonary hypertension in systemic sclerosis S. Sousa, F. Meneses, A. Cordeiro, M. J. Santos, M. J. Loureiro, C. Cotrim, C. Vinhas, C. Morais, J. R. Vieira (Almada, Portugal)
Vasodilator testing in pulmonary arterial hypertension associated with systemic sclerosis C. A. Elliot, R. M. Barraclough, I. J. Armstrong, M. Akil, D. G. Kiely (Sheffield, United Kingdom)